Should PD-L1 Expression Be Used As A Biomarker For Immunotherapy?
Executive Summary
Oncologists’ distrust of the PD-L1 biomarker was more evident at ASCO than ever. Regardless of what “marketing people” might want, immunotherapy demands more than a single biomarker, MD Anderson GU specialist Padmanee Sharma tells a packed audience on opening day. >>>Listen in to an audio clip of Genentech’s Ira Mellman discussing the company’s view.
You may also be interested in...
US FDA’s Information First Policy: PD-1 Bladder Cancer Alert Aligns With Complementary Diagnostics Perspective
Tecentriq and Keytruda's apparently lower efficacy in low PD-1/L1 patients in ongoing first-line trials prompts communication instead of restriction, underscoring FDA's emerging approach to precision medicine labeling.
Yervoy/Nivolumab May Need Stronger Survival Data To Be First Choice In Melanoma
Bristol’s combo demonstrates similar response rate as PD-1 alone, but with much better survival rates in a small melanoma study presented at ASCO. Due to toxicities, including one death, some say combination would need to shore up survival benefit to become first choice in frontline therapy.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.